B+
Bull case
30%
Probability
Target price
$130.00
Analysis reference price unavailable
Analysis 2026-08-07 · RankAlpha Sentiment Codex
RVTY
RevvityBNYSE / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexPost-earnings T+3Most likely
B
Base case
50%
Probability
Target price
$121.00
Analysis reference price unavailable
Analysis 2026-08-07 · RankAlpha Sentiment Codex
B-
Bear case
20%
Probability
Target price
$100.00
Analysis reference price unavailable
Analysis 2026-08-07 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-08-07
Recent news sentiment (30D)
-
Unavailable
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
-
Unavailable
Sentiment proxy
+60.7
Score
AI commentary
Earnings-led news tone is moderately positive after the Q2 beat and raised outlook. A secondary market-data source reports a 6.694% post-earnings gain, but the window is unspecified and no verified post-print analyst revisions were identified. The deterministic prior turned positive with improving expected returns, while tariff-refund benefits, Life Sciences softness, and divestiture execution temper conviction.
RankAlpha Sentiment Codex - 2026-08-07
Open post-earnings memoEvidence flagged
high-coverage report lacks a dated company-specific catalyst beyond generic cadence; later post-earnings follow-up lacks concrete company-source and analyst/market reaction evidence
Impact
tentative
Confidence
-
AI events
2026-08-04eventQ2 2026 beat and raised FY26 outlookMedium impact
Revvity reported Q2 revenue of $730 million, adjusted EPS of $1.41, 4% pro forma revenue growth, and 3% pro forma organic growth. Management described results as above expectations and raised FY26 pro forma revenue guidance to $2.83-$2.86 billion and adjusted EPS guidance to $5.30-$5.40 [#SEC-8K-2026-08-04].
2026-08-07catalystPost-print market reactionMedium impact
A secondary market-data page reports a 6.694% post-earnings stock-price increase, but the measurement window is unspecified. No verified post-print analyst target or estimate revision was identified, so follow-through remains uncertain.
2027-12-31catalystDiagnostics growth and portfolio reshapingHigh impact
Diagnostics delivered 11% pro forma organic growth with adjusted operating margin of 30.4%, while the company entered a definitive agreement to divest China Immunodiagnostics, approximately 6% of FY2025 revenue, with closing expected by the end of 2027 subject to approvals [#SEC-8K-2026-08-04].
Recommendation
N/A
No formal recommendation provided.
As of 2026-08-07 • Updated nightlySource: Internal modelMethodology